Acelyrin, Inc. (NASDAQ:SLRN) CEO Mina Kim Sells 17,986 Shares of Stock

Acelyrin, Inc. (NASDAQ:SLRN) CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the transaction, the chief executive officer now directly owns 671,753 shares in the company, valued at $1,840,603.22. This represents a 2.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Acelyrin Stock Down 1.1 %

Shares of SLRN opened at $2.79 on Thursday. The firm has a market cap of $279.91 million, a price-to-earnings ratio of -1.13 and a beta of 1.25. Acelyrin, Inc. has a 12 month low of $1.85 and a 12 month high of $8.59. The company’s fifty day moving average is $2.26 and its 200-day moving average is $3.84.

Acelyrin (NASDAQ:SLRN) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.07. As a group, research analysts predict that Acelyrin, Inc. will post -2.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SLRN. Wells Fargo & Company dropped their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. HC Wainwright decreased their target price on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Finally, Citigroup reduced their price objective on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.60.

Institutional Investors Weigh In On Acelyrin

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in Acelyrin in the 3rd quarter valued at approximately $50,000. HighTower Advisors LLC acquired a new stake in Acelyrin during the third quarter worth $50,000. XTX Topco Ltd acquired a new position in shares of Acelyrin in the 4th quarter valued at $33,000. 4WEALTH Advisors Inc. bought a new position in shares of Acelyrin during the 4th quarter worth about $35,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Acelyrin during the 4th quarter valued at about $36,000. 87.31% of the stock is owned by institutional investors and hedge funds.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.